Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Toronto-Dominion Bank (TD) Price & Performance

Novo Nordisk A/STrade
Toronto-Dominion BankTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Toronto-Dominion Bank — how do they compare? Novo Nordisk A/S trades at $46.22 (market cap $207.85B), while Toronto-Dominion Bank trades at $123.3 (market cap $200.48B). The key difference: Novo Nordisk A/S and Toronto-Dominion Bank are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

NVOTD
Market Cap
$207.85B$200.48B
Sector
HealthFinancials
52-Week High
$63.98$124.80
52-Week Low
$35.29$72.85
Enterprise Value
$222.55B
Dividend Yield
3.81%2.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Toronto-Dominion Bank

TD stock trades at $123.01, up 1.59% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported strong 2025 results with $61.28B revenue and $20.54B net income, though cash flow from operations was negative. Analyst consensus is positive with 9 buy ratings and no sell recommendations. Recent news highlights TD Auto Finance's industry recognition and AI-driven operational efficiencies.

The outlook is favorable given earnings momentum and dividend stability, but risks include volatile operating cash flows and high debt levels. Valuation metrics like P/E of 19.88 and P/B of 2.48 suggest reasonable pricing relative to peers, supporting a cautiously optimistic view for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Toronto-Dominion Bank

Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.

Read more on TD